• Clinical data 90%
  • Efficacy 80%
  • Secutiry 70%
  • Toxicity 30%

Eucalyptus globulus
Folium Eucalypti


Eucalyptus cordata Miq., E. diversifolia Miq., E. gigantea Dehnh., E. glauca D.C., E. globulus St Lag., E. pulverulenta Link.

General appearance

Leaf lanceolate-falcate, bifacial, 8–30cm long, 2–7cm wide; petiole twisted, strongly wrinkled, 2–3cm, occasionally 5cm, in length; apex, when present, acute or acuminate; base unequal, obtuse or somewhat rounded, margin uneven, revolute; ventral and dorsal surfaces greyish-green to pale yellowishgreen, coriaceous, glaucous, glabrous, glandular punctate, with numerous small, rounded, brown dots of cork; venation pinnate-reticulate, veins of the first order running to a short distance from margin where they are anastomosed and form a vein nearly parallel with the margin.

Major chemical constituents

Dried leaves contain 1–3% (v/w) essential oil (fresh leaves contain 0.4–1.6%), the major constituent of which is 1,8 cineole (54–95%). In addition, there are moderate amounts of other monoterpenes, including a-pinene (2.6%), pcymene (2.7%), aromadendrene, cuminaldehyde, globulol and pinocarveol. Gas chromatography and gas chromatography–mass spectroscopy of the oil indicated the presence of more than 70 components, 48 of which were identified. The concentration of a-terpeneol was estimated to be 28%. The leaves are rich in tannins and ellagitannins, and also contain 2–4% triterpenes (ursolic acid derivatives), a series of phloroglucinol-sesquiterpene coupled derivatives (macrocarpals B, C, D, E, H, I and J) and flavonoids (rutin, quercetin, quercitrin and hyperoside).

Medicinal uses of Eucalyptus globulus

Uses supported by clinical data
Uses described in pharmacopoeias and in traditional systems of medicine
Eucalyptus globulus as an expectorant for symptomatic treatment of mild inflammation of the respiratory tract and bronchitis. Also for symptomatic treatment of asthma, fever and inflammation of the throat.
Uses described in folk medicine, not supported by experimental or clinical data
Treatment of cystitis, diabetes, gastritis, kidney disease (unspecified), laryngitis, leukorrhoea, malaria, pimples, ringworm, wounds, ulcers of the skin, urethritis and vaginitis.


Experimental pharmacology

Antibacterial and antifungal activity

An ethanol–water extract of Folium Eucalypti inhibited the growth in vitro of Staphylococcus aureus at a concentration of 25mg/ml. An aqueous leaf extract inhibited the growth in vitro of Escherichia coli, Staphylococcus aureus, Bacillus subtilis and Enterococcus faecalis (MIC 0.07–1.30mg/ml). A methanol extract of the leaves inhibited the growth in vitro of Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans (MIC 1.25–10.00mg/ml). A fluidextract of the leaves inhibited the growth in vitro of Mycobacterium tuberculosis (MIC 6.25mg/ml) (24). A methanol–water extract of the leaves inhibited the growth in vitro of Candida albicans.

Antiviral activity

An aqueous leaf extract inhibited the replication of influenza virus A2 (Mannheim 57), vaccinia virus and herpes simplex virus type 2 in vitro at a concentration of 0.1%.

Antimalarial activity

Intragastric administration of a hexane leaf extract to mice (100mg/kg body weight) did not inhibit the growth of Plasmodium berghei. Furthermore, administration of an aqueous (3.48 g/kg body weight) or chloroform (264mg/kg body weight) leaf extract to chickens by gastric lavage did not inhibit the growth of P. gallinaceum. An ethanol–water extract of the leaves inhibited the growth in vitro of P. falciparum at a concentration of 75mg/ml.

Antidiabetes activity

A hot aqueous extract of the leaves suppressed streptozocin-induced hyperglycaemia in mice when added to the diet (6.25%) and drinking-water (0.25%). The same extract did not stimulate insulin production by the pancreas. However, intragastric administration of aqueous or ethanol extracts of the leaves at a dose of 1 g/kg body weight did not suppress alloxan-induced hyperglycaemia in mice and rabbits.

Clinical pharmacology



Preparations of Folium Eucalypti should not be administered internally to children or patients with inflammation of the gastrointestinal tract, gall bladder disease or impaired liver function.


Folium Eucalypti preparations should not be applied to the face, especially the nose, of infants or young children. Keep out of reach of children.

News and Journals

1. African pharmacopoeia. Vol. 1, 1st ed. Lagos, Organization of African Unity, Scientific,
Technical & Research Commission, 1985.
2. British herbal pharmacopoeia. London, British Herbal Medicine Association, 1996.
3. European pharmacopoeia, 3rd ed., Suppl. 2000. Strasbourg, Council of Europe, 1999.
4. Blaschek W et al., eds. Hagers Handbuch der pharmazeutischen Praxis. Folgeband 2:
Drogen A–K, 5th ed. Berlin, Springer-Verlag, 1998.
5. Farnsworth NR, ed. NAPRALERT database. Chicago, University of Illinois at
Chicago, IL, February 14, 1998 production (an online database available directly
through the University of Illinois at Chicago or through the Scientific and Technical
Network [STN] of Chemical Abstracts Services).
6. Iwu MM. Handbook of African medicinal plants. Boca Raton, FL, CRC Press, 1993.
7. Newall CA, Anderson LA, Phillipson JD. Herbal medicines, a guide for health-care
professionals. London, The Pharmaceutical Press, 1996.
8. Youngken HW. Textbook of pharmacognosy, 6th ed. Philadelphia, PA, Blakiston, 1950.
9. Heyne K. De nuttige planten van Indonesie, 3rd ed. Wageningen, H. Veenman & Konen,
10. Bisset NG. Herbal drugs and phytopharmaceuticals. Boca Raton, FL, CRC Press, 1994.
11. Backer CA, van den Brink B. Flora of Java. Vol. 2. Groningen, Netherlands, NVP
Noordhof, 1965.
12. Bruneton J. Pharmacognosy, phytochemistry, medicinal plants. Paris, Lavoisier, 1995.
13. Wagner H, Bladt S. Plant drug analysis, 2nd ed. Berlin, Springer-Verlag, 1996.
14. Quality control methods for medicinal plant materials. Geneva, World Health Organization,
15. European pharmacopoeia, 3rd ed. Strasbourg, Council of Europe, 1996.
16. Guidelines for predicting dietary intake of pesticide residues, 2nd rev. ed. Geneva, World
Health Organization, 1997 (document WHO/FSF/FOS/97.7).
17. Zhao ZD et al. Gas chromatography of residue from fractional distillation of
Eucalyptus globulus leaf oil. Linchan Huaxue Yu Gongye, 1997, 17:37–40.
18. Nishizawa M et al. Macrocarpals: HIV-RTase inhibitors of Eucalyptus globulus.
Tetrahedron Letters, 1992, 33:2983–2986.
19. Osawa K et al. Macrocarpals H, I, and J from the leaves of Eucalyptus globulus. Journal
of Natural Products, 1996, 59:823–827.
20. Blumenthal M et al., eds. The complete German Commission E monographs. Austin,
TX, American Botanical Council, 1998.
21. Aswal BS et al. Screening of Indian plants for biological activity. Part X. Indian Journal
of Experimental Biology, 1984, 22:312–322.
22. Brantner A, Grein E. Antibacterial activity of plant extracts used externally in
traditional medicine. Journal of Ethnopharmacology, 1994, 44:35–40.
23. Navarro V et al. Antimicrobial evaluation of some plants used in Mexican traditional
medicine for the treatment of infectious diseases. Journal of Ethnopharmacology, 1996,
24. Fitzpatrick FK. Plant substances active against Mycobacterium tuberculosis. Antibiotics
and Chemotherapy, 1954, 4:528.
25. Cacerea A et al. Plants used in Guatemala for the treatment of dermatophytic infections.
Screening for antimycotic activity of 44 plant extracts. Journal of Ethnopharmacology,
1991, 31:263–276.
26. May G, Willuhn G. Antiviral activity of aqueous extracts from medicinal plants in
tissue cultures. Arzneimittel-Forschung, 1978, 28:1–7.
27. Brandao M et al. Antimalarial experimental chemotherapy using natural products.
Ciência e Cultura Sociedad Brasileira para o Progresso da Ciência, 1985, 37:1152–1163.
28. Spencer CF et al. Survey of plants for antimalarial activity. Lloydia, 1947, 10:145–
174.29. Swanson-Flatt SK et al. Traditional plant treatments for diabetes. Studies in normal
and streptozotocin-diabetic mice. Diabetologia, 1990, 33:462–464.
30. Lin YC et al. Studies on the hypoglycemic activity of the medical herbs. Formosan
Medical Association, 1964, 63:400–404.
31. Perez RM et al. A study of the hypoglycemic effect of some Mexican plants. Journal
of Ethnopharmacology, 1984, 12:253–262.
32. Corrigan D. Eucalyptus species. In: DeSmet PAGM et al., eds. Adverse reactions of
herbal drugs. Berlin, Springer-Verlag, 1992:125–133.
33. Schimmer O et al. An evaluation of 55 commercial plant extracts in the Ames mutagenicity
test. Pharmazie, 1994, 49:448–451.
34. Pages N et al. The essential oils and their potential teratogenic properties: example
of the essential oils of Eucalyptus globulus preliminary study with mice. Plantes
médicinales et Phytotherapie, 1990, 24:21–26.
35. Jori A, Briatico G. Effects of eucalyptol on microsomal enzyme activity of foetal and
newborn rats. Biochemical Pharmacology, 1973, 22:543–544.
36. Mitchell J, Rook J. Botanical dermatology. Vancouver, Greengrass, 1979:484–486.